TherapeuticsMD (NASDAQ:TXMD) Shares Down 1.6% – Here’s What Happened

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s share price traded down 1.6% during mid-day trading on Friday. The stock traded as low as $1.80 and last traded at $1.80. Approximately 3,832 shares traded hands during trading, a decline of 81% from the average daily volume of 20,304 shares. The stock had previously closed at $1.83.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered TherapeuticsMD from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

TherapeuticsMD Price Performance

The firm has a market capitalization of $20.83 million, a PE ratio of 90.00 and a beta of 0.65. The company has a 50-day moving average price of $2.05 and a 200-day moving average price of $2.12.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Tuesday, August 11th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($6.12) by $6.13. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%. The firm had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $19.77 million.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its stake in TherapeuticsMD stock. Renaissance Technologies LLC lifted its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 51.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 146,200 shares of the company’s stock after buying an additional 49,700 shares during the quarter. Renaissance Technologies LLC owned approximately 1.26% of TherapeuticsMD worth $295,000 at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States.

The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.